AI assistant
Denali Therapeutics Inc. — Director's Dealing 2021
Jan 13, 2021
31637_dirs_2021-01-12_e00164da-da87-46d6-8d07-1c362c742054.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-01-08
Reporting Person: Thornberry Nancy (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-01-08 | Stock Option (right to buy) | $80.03 | A | 7535 | Acquired | 2031-01-07 | Common Stock (7535) | Direct |
| 2021-01-08 | Restricted Stock Units | $ | A | 2511 | Acquired | Common Stock (2511) | Direct |
Footnotes
F1: 25% of the shares subject to the option shall vest on January 8, 2022, and an additional 1/48 of the shares subject to the option vest each month thereafter, subject to the Reporting Person remaining a non-employee director of the Issuer through each such date.
F2: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F3: 25% of the restricted stock units shall vest on January 8, 2022 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a non-employee director of the Issuer through each such date.